Загрузка...
Optimizing therapy for mantle cell lymphoma
Most people with mantle cell lymphoma (MCL) present with diffuse adenopathy and benefit from early initiation of rituximab and high-dose cytarabine- or bendamustine-based therapies. Some patients, however, present with primarily nonnodal disease that can follow either an indolent or a rapidly progre...
Сохранить в:
| Опубликовано в: : | Hematology Am Soc Hematol Educ Program |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142585/ https://ncbi.nlm.nih.gov/pubmed/29222271 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|